Back to Home

Affordability & Price Transparency

Expert articles and analysis related to affordability & price transparency.

200 articlesLast 30 Days

AI Summary — Last 30 Days

Affordability and transparency are becoming more operationally consequential for VBC as CMS tightens prior authorization reporting across MA, Medicaid managed care, and ACA Marketplace plans, while 2025 data show at least 1 in 8 standard PA requests are denied—raising pressure on risk-bearing providers to manage access friction, documentation burden, and member experience more proactively (KFF prior authorization analysis). At the same time, the 2025 reconciliation law’s limits on Medicaid state directed payments could reduce hospital-directed Medicaid funding in at least 37 states, creating a margin shock that may accelerate provider interest in accountable care, population health infrastructure, and payer-provider alignment—but also intensify disputes over whether VBC can offset lost supplemental payment streams (KFF Medicaid directed payments analysis). Medicare Advantage remains strategically unsettled, with large insurers pulling back even as players like SCAN and nontraditional entrants test contrarian growth strategies, signaling that affordability pressure is shifting competition toward narrower risk selection, administrative efficiency, and differentiated care management rather than simple enrollment expansion.

Related Articles

95ALN

A tragedy of epic proportions looms for healthcare

Garrett Hardin popularized the idea of a tragedy of the commons in a 1968 Science essay carrying that title.[1] It describes a situation in which individuals with unlimited access to a public resource...

HFMAJul 28, 2026
95ALN

The rise and consequences of PBM vertical integration

Decades ago, PBMs were independent operators, but now, the biggest ones are vertically integrated with healthcare conglomerates.

Healthcare BrewJul 28, 2026
95ALN

What appeals court 340B rebate decision means for federal rebates

An appeals court barred 340B rebate programs by drug manufacturers, among recent legal developments. The case could have ramifications for federal 340B rebates. On July 21, the U.S. Court of Appeals f...

HFMAJul 28, 2026
95ALN

How Has ACA Marketplace Enrollment Changed Across States in 2026?

Following several years of rapid enrollment growth in the Affordable Care Act (ACA) Marketplaces that corresponded with temporary enhanced premium tax credits, enrollment fell for the first time in se...

KFFJul 28, 2026
95ALN

The Limits of Disclosure and the Power of the Outside Option: A Case for External Reference Pricing in Healthcare

By DAVID INTROCASO & ADAM CUNNINGHAM For over a decade, federal healthcare policy has operated on a foundational premise: if hospital prices are made visible, market discipline will inevitably follow....

The Healthcare BlogJul 28, 2026
95ALN

Drug pricing and the IRA: Tracking the government's negotiation power

Drug pricing and the IRA: Tracking the government's negotiation power  Endpoints News

Endpoints NewsJul 26, 2026
92ALN

Brand Drugmakers’ Patent Abuse Is Raising Americans’ Healthcare Costs by Billions Each Year

Brand Drugmakers’ Patent Abuse Is Raising Americans’ Healthcare Costs by Billions Each Year  AHIP

AHIPJul 27, 2026
92ALN

The $48B Payor Nobody Contracts With

Executive Summary While You Were Fighting the 800 Pound Managed Care Gorilla, a New Payor Walked In Every hospital CFO can recite their payor mix from memory: Medicare, Medicaid, commercial, self-pay....

HospitalogyJul 27, 2026
90ALN

Emerging 2026 ACA Data: Enrollment Drops 12% as Relative Risk Rises 6.3%

New data show a smaller, higher-risk ACA individual market emerging after enhanced premium tax credits expired. In Wakely’s new white paper, 2026 Individual Market Risk Pool Considerations: Emerging D...

WakelyJul 28, 2026
90ALN

New Analysis Highlights Opportunities to Improve MPPP Uptake

AvalereJul 28, 2026